MA43701A - Dérivés de pyrrolidine spiro-fusionnés en tant qu'inhibiteurs des enzymes de désubiquitination (dub) - Google Patents
Dérivés de pyrrolidine spiro-fusionnés en tant qu'inhibiteurs des enzymes de désubiquitination (dub)Info
- Publication number
- MA43701A MA43701A MA043701A MA43701A MA43701A MA 43701 A MA43701 A MA 43701A MA 043701 A MA043701 A MA 043701A MA 43701 A MA43701 A MA 43701A MA 43701 A MA43701 A MA 43701A
- Authority
- MA
- Morocco
- Prior art keywords
- dub
- spiro
- fusion
- enzyme inhibitors
- pyrrolidine derivatives
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 230000009504 deubiquitination Effects 0.000 title 1
- 239000002532 enzyme inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603779.8A GB201603779D0 (en) | 2016-03-04 | 2016-03-04 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43701A true MA43701A (fr) | 2018-11-28 |
Family
ID=55859019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043701A MA43701A (fr) | 2016-03-04 | 2017-03-02 | Dérivés de pyrrolidine spiro-fusionnés en tant qu'inhibiteurs des enzymes de désubiquitination (dub) |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10654853B2 (fr) |
| EP (2) | EP4067355A1 (fr) |
| JP (2) | JP6959247B2 (fr) |
| KR (1) | KR102384139B1 (fr) |
| CN (1) | CN108602823B (fr) |
| AU (1) | AU2017225371B2 (fr) |
| BR (1) | BR112018017086B1 (fr) |
| CA (1) | CA3016370C (fr) |
| CO (1) | CO2018009275A2 (fr) |
| ES (1) | ES2919549T3 (fr) |
| GB (1) | GB201603779D0 (fr) |
| IL (1) | IL261552B (fr) |
| MA (1) | MA43701A (fr) |
| MX (1) | MX382562B (fr) |
| MY (1) | MY196836A (fr) |
| RU (1) | RU2730552C2 (fr) |
| SG (1) | SG11201807301SA (fr) |
| WO (1) | WO2017149313A1 (fr) |
| ZA (1) | ZA201803910B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3277677T (lt) | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (fr) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines en tant qu'inhibiteurs des dub pour le traitement du cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) * | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7208931B2 (ja) | 2017-06-20 | 2023-01-19 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (fr) | 2018-08-14 | 2026-06-17 | Amgen Inc. | Derives de n-cyano-7-azanorbonane et leurs applications |
| EP4218934B1 (fr) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibition de la protéase 30 spécifique de l'ubiquitine (usp30) |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| KR20230016674A (ko) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
| WO2021245186A1 (fr) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines ayant une activité en tant qu'inhibiteurs de l'usp30 |
| RS67140B1 (sr) | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| CN116143782B (zh) * | 2021-11-22 | 2024-04-12 | 西南大学 | 一类螺[吡咯烷-2,3'-喹啉]-2'-酮类衍生物的设计合成与应用 |
| WO2023099561A1 (fr) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30 |
| JP2025500506A (ja) * | 2021-12-23 | 2025-01-09 | ザ・カトリック・ユニヴェルシテイト・ルーバン | Ｙａｐ／ｔａｚ－ｔｅａｄを阻害するためのスピロ及び関連類似体 |
| WO2024151847A1 (fr) * | 2023-01-13 | 2024-07-18 | The University Of North Carolina At Chapel Hill | Identification de 7bi d'inhibiteur de otud7b et son application dans la réduction de la croissance de cellules cpnpc et leucémiques |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| US7759383B2 (en) | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| CA2661354C (fr) * | 2006-08-30 | 2012-12-18 | The Regents Of The University Of Michigan | Nouvelles petites molecules inhibitrices de mdm2 et leurs utilisations |
| WO2008144507A2 (fr) | 2007-05-16 | 2008-11-27 | President And Fellows Of Harvard College | Inhibiteurs de spirooxindole de kinase de l'aurore |
| US20090264431A1 (en) * | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| TR201807311T4 (tr) * | 2011-03-10 | 2018-06-21 | Daiichi Sankyo Co Ltd | Dispiropirolidin derivesi. |
| EP2752191A1 (fr) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions et procédés utilisant un antagoniste de hdm2 et un inhibiteur de mek |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (fr) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines en tant qu'inhibiteurs des dub pour le traitement du cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2016
- 2016-03-04 GB GBGB1603779.8A patent/GB201603779D0/en not_active Ceased
-
2017
- 2017-03-02 ES ES17709766T patent/ES2919549T3/es active Active
- 2017-03-02 SG SG11201807301SA patent/SG11201807301SA/en unknown
- 2017-03-02 KR KR1020187028269A patent/KR102384139B1/ko active Active
- 2017-03-02 MA MA043701A patent/MA43701A/fr unknown
- 2017-03-02 WO PCT/GB2017/050565 patent/WO2017149313A1/fr not_active Ceased
- 2017-03-02 US US16/078,518 patent/US10654853B2/en active Active
- 2017-03-02 BR BR112018017086-0A patent/BR112018017086B1/pt active IP Right Grant
- 2017-03-02 MX MX2018008271A patent/MX382562B/es unknown
- 2017-03-02 AU AU2017225371A patent/AU2017225371B2/en active Active
- 2017-03-02 MY MYPI2018001499A patent/MY196836A/en unknown
- 2017-03-02 EP EP22172828.0A patent/EP4067355A1/fr not_active Withdrawn
- 2017-03-02 CN CN201780010388.5A patent/CN108602823B/zh active Active
- 2017-03-02 CA CA3016370A patent/CA3016370C/fr active Active
- 2017-03-02 EP EP17709766.4A patent/EP3423454B1/fr active Active
- 2017-03-02 JP JP2018546518A patent/JP6959247B2/ja active Active
- 2017-03-02 RU RU2018133279A patent/RU2730552C2/ru active
-
2018
- 2018-06-12 ZA ZA2018/03910A patent/ZA201803910B/en unknown
- 2018-09-02 IL IL261552A patent/IL261552B/en active IP Right Grant
- 2018-09-04 CO CONC2018/0009275A patent/CO2018009275A2/es unknown
-
2020
- 2020-04-08 US US16/843,408 patent/US11236092B2/en active Active
-
2021
- 2021-09-29 JP JP2021158986A patent/JP7280928B2/ja active Active
- 2021-12-14 US US17/550,071 patent/US20220106315A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261552B (en) | Spiro-condensed pyrrolidine derivatives that inhibit deubiquitination enzymes (dub) | |
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| EP3992189A4 (fr) | Dérivés de quinazoline et de cinnoline en tant qu'inhibiteurs de l'adn-pk | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| EP3416964A4 (fr) | Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| EP3601239A4 (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| EP3737421A4 (fr) | Procédés de production, purification et formulation de conjugués anticorps-médicaments | |
| EP3778605A3 (fr) | Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation | |
| EA201892128A1 (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
| MX383652B (es) | Moduladores de la vía de estrés integrada. | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| ME03574B (fr) | Composés hétéroaryle utiles en tant qu'inhibiteurs de l'enzyme d'activation sumo | |
| MA41291A (fr) | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer | |
| MA42810A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| EP3946288A4 (fr) | Dérivés de 5-cyclopropyl-1h-pyrazol-3-yl-amine substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13 | |
| EP3541374A4 (fr) | Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2 | |
| MA49127A (fr) | Dérivés d'indole n-substitués | |
| MA50439A (fr) | Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 |